PARP1 and prostate carcinoma: Specifically, we selected 12 genes that were assessed as a biomarker to stratify patients with castration-resistant prostate cancer for olaparib treatment in a recent phase 2 clinical trial and 11 additional genes reported to be involved in DNA damage repair or sensitivity to PARP inhibition (Supplementary Table 4)15.